久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國MDxHealth  
MDxHealth是一家分子診斷公司，開發(fā)和銷售先進(jìn)的測試為癌癥患者評估和個(gè)性化的治療。

申請專利的DNA甲基化平臺和生物標(biāo)志物，我們幫助解決龐大且不斷增長的未滿足的醫(yī)療需求，為更好的癌癥診斷和治療的信息。

MDxHealth是一個(gè)公開上市的公司在紐約泛歐交易所集團(tuán)（在紐約證券交易所，紐約證券交易所）代號“MDXH”布魯塞爾和阿姆斯特丹的市場交易。

MDxHealth（原名Oncomethylome Sciences公司）成立于2003年，總部設(shè)在比利時(shí)。其美國總部位于北卡羅來納州達(dá)勒姆。

MDxHealth自身或與制藥公司合作開發(fā)分子診斷產(chǎn)品。其部分產(chǎn)品已經(jīng)商業(yè)化和公司的其他產(chǎn)品有廣泛的管道為主要癌癥的跡象。

MDxHealth is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients.

Applying our patented DNA methylation platform and biomarkers, we help address a large and growing unmet medical need for better cancer diagnosis and treatment information.

MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH".

MDxHealth (formerly OncoMethylome Sciences) was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Durham, NC.

MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.